Intent to treat analysis | ||||||
---|---|---|---|---|---|---|
KRASwild-type | KRASmutant | All | ||||
No | % | No | % | No | % | |
Enrolled patients | 31 | 100 | 28 | 100 | 59 | 100 |
Evaluable patients | 30 | 97 | 27 | 96 | 57 | 97 |
Objective response | 27 | 90 (95% CI 79 to 100) | 18 | 67 (95% CI 49 to 85) | 45 | 79 (95% CI 68 to 100) |
Partial response | 23 | 77 | 17 | 63 | 40 | 70 |
Complete response | 4 | 13 | 1 | 4 | 4 | 7 |
Stable disease | 2 | 7 | 5 | 18.5 | 7 | 12 |
Progressive disease | 1 | 3 | 4 | 15 | 5 | 9 |
Median PFS, months | 14 | 11 | 12 | |||
Range | 1+-69+ | 1+-60+ | 1+-69+ | |||
Progression events | 25 | 81 | 20 | 71 | 45 | 76 |
Median OS, months | 38 | 20 | 28 | |||
Range | 1+-69+ | 1+-60+ | 1+-69+ | |||
Deaths | 17 | 55 | 17 | 61 | 34 | 58 |
Liver metastasectomies | 11 | 7 | 18 | |||
No/overall patients | 11/31 | 35 | 7/28 | 25 | 18/59 | 31 |
No/patients with liver metastases | 11/19 | 58 | 7/20 | 35 | 18/39 | 46 |
No/patients with L-L metastases | 10/12 | 83 | 7/13 | 54 | 17/25 | 68 |
Pathologic complete responses | - | - | 2 | 28.5 | 2 | 11 |